Valuation dashboard for Nexalin Technology, Inc. (NXL) with P/E N/A, P/B 2.28, EV/EBITDA -0.30 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia.
Analysis Summary
Nexalin Technology, Inc. reported revenue of $301647 in the most recent fiscal year, growing at a 5-year CAGR of 4.4%.
Trailing-twelve-month margins: gross margin -148.4%, operating margin -42.0%, net margin -41.4%.
At the current price of $4.92, NXL has negative trailing earnings (P/E not meaningful) and an ROE of -278.25%. Market capitalisation stands at $4M.
Balance sheet quality for NXL: current ratio of 4.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.28 |
| EV / EBITDA | -0.30 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-8.80 |
| vs Current Price | -278.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NXL | Nexalin Technology, Inc. | $4M | 2.28 | -278.2% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price
| Price | $4.92 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -278.25% |
| Return on Invested Capital | -600.62% |
| Return on Assets | -299.21% |
| Gross Margin | -148.42% |
| Operating Margin | -4202.54% |
| Net Margin | -4139.38% |
Related companies: CLGN · ENLV · HBIO · IINN · MODD · NRXS · RBOT
Explore sector: Healthcare · Medical - Devices
More sections of NXL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks